Streetbeat News

PBLA

Panbela Therapeutics Inc.

http://www.sunbiopharma.com/

CEO

Michael Cullen

Open

0.31

Mkt cap

1.7M

Volume

2

High

0.32

P/E Ratio

-0.01

52-wk high

38.00

Low

0.31

Div yield

N/A

52-wk low

0.30

Panbela Therapeutics, Inc. held its Q3 2024 earnings call, with CEO Jennifer Simpson and CFO Sue Horvath presenting. The call included a formal presentation followed by a Q&A session.

Portfolio Pulse from

November 14, 2024 | 11:45 pm

Panbela Therapeutics, Inc. (OTCQB: PBLA) has released its Q3 2024 financial results and provided a business update. The company, which focuses on developing therapeutics for urgent unmet medical needs, will host an earnings call to discuss these results.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Neutral rating on Panbela Therapeutics (OTC:PBLA).

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 10:15 am

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Neutral rating on Panbela Therapeutics (OTC:PBLA).

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 5:06 pm

HC Wainwright & Co. has downgraded Panbela Therapeutics from Buy to Neutral, as per analyst Joseph Pantginis.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 5:31 pm

Panbela Therapeutics (NASDAQ:PBLA) reported a Q1 2024 GAAP EPS of $(2.28), significantly missing the analyst consensus estimate of $(1.48) by 54.05%.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 8:21 pm

HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Panbela Therapeutics (PBLA) but lowers the price target from $16 to $5.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:49 pm

Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Panbela Therapeutics (PBLA) and kept the price target at $25.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 3:59 pm

Panbela Therapeutics (OTC:PBLA) reported Q4 earnings with an EPS of $-65.9, missing estimates by -171.0% and showing no revenue change from the previous year. Despite past earnings misses leading to share price increases, this significant miss could impact investor sentiment.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 8:55 pm

Panbela Therapeutics (NASDAQ:PBLA) reported a Q4 2023 GAAP EPS loss of $(65.90), significantly missing the analyst consensus estimate of $(24.34) by 170.75%.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 8:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.